Singapore markets close in 12 minutes

Relay Therapeutics, Inc. (RLAY)

NasdaqGM - NasdaqGM Real-time price. Currency in USD
Add to watchlist
6.35+0.45 (+7.63%)
At close: 04:00PM EDT
6.62 +0.27 (+4.25%)
After hours: 07:47PM EDT
Full screen
Trade prices are not sourced from all markets
Previous close5.90
Open5.87
Bid6.33 x 600
Ask6.36 x 300
Day's range5.71 - 6.43
52-week range5.70 - 13.32
Volume1,705,688
Avg. volume1,204,450
Market cap840.327M
Beta (5Y monthly)1.63
PE ratio (TTM)N/A
EPS (TTM)N/A
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
All
News
  • GlobeNewswire

    Relay Therapeutics to Participate in Upcoming Investor Conferences

    CAMBRIDGE, Mass., April 11, 2024 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies, today announced that management will participate in three upcoming fireside chats: Stifel 2024 Virtual Targeted Oncology Forum on Wednesday, April 17, 2024 at 1:00 p.m. ETThe Citizens JMP Life Sciences Conference on Tuesday, May 14, 2024 at 11:30 a.m.

  • GlobeNewswire

    Relay Therapeutics to Participate in Three Upcoming Investor Conferences

    CAMBRIDGE, Mass., Feb. 26, 2024 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies, today announced that management will participate in three upcoming fireside chats: TD Cowen’s 44th Annual Health Care Conference on Monday, March 4, 2024 at 10:30 a.m. ETLeerink Partners’ 2024 Global Biopharma Conference on Monday, March 11, 2024 at 10

  • GlobeNewswire

    Relay Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Corporate Highlights

    Completed enrollment in initial RLY-2608 600mg + fulvestrant dose expansion cohort & initiated additional dose expansion cohorts with RLY-2608 400mg & 600mg Initiated RLY-2608 + fulvestrant + ribociclib triplet combination in PI3Kα-mutated HR+/HER2- metastatic breast cancer Approximately $750 million in cash, cash equivalents and investments at end of Q4 2023, expected to fund operations into second half of 2026 CAMBRIDGE, Mass., Feb. 22, 2024 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq